1541 — ImmuneOnco Biopharmaceuticals (Shanghai) Share News
0.000.00%
Last trade - 00:00- HK$1.57bn
- HK$660.22m
- CNY154.29m
Brief: Immuneonco Biopharmaceuticals Shanghai Disposes Of Stake In Unit
Brief: Immuneonco Biopharmaceuticals Shanghai Gets Approval By NMPA For Phase II Clinical Trial Of IMM0306
HK-listed ImmuneOnco Biopharma slumps on discounted share sale
Brief: Immuneonco Biopharmaceuticals Shanghai Announces Placing Of New H Shares
Brief: Immuneonco Biopharmaceuticals Shanghai Nominates Zhang Ruliang As Executive Director
Brief: Immuneonco Biopharmaceuticals Shanghai Subscribes Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Announces Registrational Strategy In Collaboration With Instil
Brief: Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Received Near-Term Payment Of $5 Mln From Synbiotx
Brief: Immuneonco Biopharmaceuticals Shanghai Noted Recent Unusual Fluctuations In Price Of Shares Of Co
Brief: Immuneonco Biopharmaceuticals Shanghai Posts HY Loss Of RMB165.8 Mln
Brief: Immuneonco Biopharmaceuticals Shanghai Announces License And Collaboration Agreement
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Says Obtained Investigational New Drug Approval For Phase Ib/Iii Clinical Trial Of Imc-002 From Nmpa
Brief: Immuneonco Biopharmaceuticals Shanghai Says Approval By NMPA For Phase III Clinical Trial Of IMM01
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Says Guan Mei Appointed As Executive Director Of First Session Of Board
Brief: Immuneonco Biopharmaceuticals Shanghai Says Approval By NMPA
Brief: Immuneonco Biopharmaceuticals Shanghai Says Approval By NMPA For Phase III Clinical Trial
Brief: Immuneonco Biopharmaceuticals Shanghai Posts Loss For Year RMB379.5 Mln
Brief: Immuneonco Biopharmaceuticals Shanghai Gets Orphan-Drug Designation From FDA